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Abstract
Background: Atypical hyperplasia (AH) and mammographic breast density (MBD) are established risk factors for
breast cancer (BC), but their joint contributions are not well understood. We examine associations of MBD and BC by
histologic impression, including AH, in a subcohort of women from the Mayo Clinic Benign Breast Disease Cohort.
Methods: Women with a diagnosis of BBD and mammogram between 1985 and 2001 were eligible. Histologic
impression was assessed via pathology review and coded as non-proliferative disease (NP), proliferative disease without
atypia (PDWA) and AH. MBD was assessed clinically using parenchymal pattern (PP) or BI-RADS criteria and categorized
as low, moderate or high. Percent density (PD) was also available for a subset of women. BC and clinical information
were obtained by questionnaires, medical records and the Mayo Clinic Tumor Registry. Women were followed from
date of benign biopsy to BC, death or last contact. Standardized incidence ratios (SIRs) compared the observed
number of BCs to expected counts. Cox regression estimated multivariate-adjusted MBD hazard ratios.
Results: Of the 6271 women included in the study, 1132 (18.0%) had low MBD, 2921 (46.6%) had moderate MBD, and
2218 (35.4%) had high MBD. A total of 3532 women (56.3%) had NP, 2269 (36.2%) had PDWA and 470 (7.5%) had AH.
Over a median follow-up of 14.3 years, 528 BCs were observed. The association of MBD and BC risk differed by histologic
impression (p-interaction = 0.03), such that there was a strong MBD and BC association among NP (p < 0.001) but
non-significant associations for PDWA (p = 0.27) and AH (p = 0.96). MBD and BC associations for AH women were not
significant within subsets defined by type of MBD measure (PP vs. BI-RADS), age at biopsy, number of foci of AH, type
of AH (lobular vs. ductal) and body mass index, and after adjustment for potential confounding variables. Women with
atypia who also had high PD (>50%) demonstrated marginal evidence of increased BC risk (SIR 4.98), but results were
not statistically significant.
Conclusion: We found no evidence of an association between MBD and subsequent BC risk in women with AH.
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Background
Breast biopsies are commonly performed to investi-
gate BC in women with suspicious mammographic or
palpable findings, and the majority of them reveal
only benign breast lesions. In fact, of the estimated
1.6 million breast biopsies performed in the United
States each year [1], approximately 80% are found to
be benign [2]. The histologic features of these benign
breast disease (BBD) findings are quite varied and can
be used to stratify women into groups with signifi-
cantly different risks of developing a later BC [3, 4].
Atypical hyperplasia (AH) is a high-risk benign lesion
found in approximately 10% of benign biopsies [5]
and is composed of two histologic subtypes: atypical
ductal hyperplasia (ADH) and atypical lobular hyper-
plasia (ALH). We and others have previously reported
that women with AH are at an approximately four-
fold risk of subsequent BC [3, 4, 6, 7], and have an
approximate 30% cumulative risk at 25 years post bi-
opsy [8]. This long-term risk is similar for women
with ADH and those with ALH [6, 8].
In a recent review article we suggested that clinicians
consider the use of screening MRIs and pharmacologic
agents such as aromatase inhibitors (AIs) and selective
estrogen receptor modulators (SERMs) as potential pre-
ventive options for women with AH [9]. However, we
also recognize that many women diagnosed with AH will
never progress to BC. Clinical prevention measures can
be costly, and pharmacological agents can induce ad-
verse side effects. Thus, it is important to identify risk
factors among women with AH that further stratify BC
risk in order to target screening and prevention efforts
to those with the highest risk.
Mammographic breast density (MBD), which represents
the proportion of tissues that appear white or dense on a
mammogram, is a well-established risk factor for breast
cancer [10–12]. Women with high MBD have a 3–5 fold
increased risk of BC relative to those with low density
[13, 14]. It has also been shown that AH is associated
with increased MBD [15]. However, to date there
have been very few studies examining the association
of MBD with BC risk in women with AH, with in-
consistent findings. Byrne et al. found no association
between percent density and risk in women with AH
[16]. Conversely, two other studies have reported in-
creased risk in women with AH who have high MBD
[17, 18], although small sample sizes limit the signifi-
cance of the associations. We previously reported no
association between MBD [measured by Wolfe’s par-
enchymal pattern (PP)] and BC risk in a group of 147
women with AH [19]. Here, we present results in an
expanded cohort of 470 women diagnosed with AH
between 1985 and 2001 to examine if MBD can fur-
ther stratify BC risk in women with AH.
Methods
Study setting and population
The Mayo Clinic Benign Breast Disease study has been de-
scribed previously [3] and currently comprises 13,527
women ages 18 to 85 who underwent a benign breast bi-
opsy between 1967 and 2001 at Mayo Clinic in Rochester,
MN. Detailed demographic and clinical features and risk
factors were identified from medical records and question-
naires [3]. BC events were ascertained from study question-
naires, tumor registry, and review of medical records. The
study protocol, including patient contact and follow-up
methods, was approved by the Mayo Clinic Institutional
Review Board. We excluded all women who refused to
allow use of their medical record for research. All women
in the BBD cohort with a biopsy between 1985 and 2001
and for whom MBD was available from clinical
records,were included in this particular study.
Histologic examination
The study breast pathologist (DWV) performed histo-
logic review of archived hematoxylin-and-eosin (H&E)
slides from the benign biopsies. Histology was classified
according to the criteria of Page et al. [4, 7] into the fol-
lowing categories: nonproliferative disease (NP), prolifer-
ative disease without atypia (PDWA), and AH. The
degree of lobular involution (LI) for each individual was
categorized as described previously [20].
Assessment of mammographic breast density
MBD was available from medical records starting in 1985.
From 1985 to June 1996, MBD was measured at Mayo
Clinic using Wolfe’s four-category parenchymal pattern (PP)
criteria [21]: N1—non-dense, no ducts visible; P1—ductal
prominence occupying less than a fourth of the breast;
P2—prominent ductal pattern occupying more than a fourth
of the breast; and DY—homogenous, plaque-like areas of
extreme density [21]. From July 1996 to 2001 MBD was
measured using the four density categories of the American
College of Radiology Breast Imaging Reporting and Data
System (BI-RADS) [22]: almost entirely fat (low density);
scattered fibroglandular densities (average density); hetero-
geneously dense (high density); extremely dense (very high
density). For the primary analyses, the density measures
above were categorized as low, moderate or high MBD by
combining the middle two categories for each (Fig. 1).
Retrieval of mammogram films was attempted on all
women with AH over this period. Clinical practice gen-
erally saved mammogram films for a ten year period. All
available mammographic films were digitized using an
Array 2905 laser digitizer (Array Corporation,
Netherlands) that has 50 micrometer (limiting) pixel
spacing with 12-bit gray scale bit depth. A single expert
reader, blinded to BC status, calculated mammographic
percent density using the craniocaudal view of the
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noncancerous breast of women who progressed to breast
cancer and the left breast of unaffected women. Percent
mammographic density, defined as dense area divided by
total area x 100%, was calculated using Cumulus, a
computer-assisted thresholding program [23]. Five per-
cent of images were repeated to assess reliability, with a
resulting intraclass correlation exceeding 0.93. For the
purposes of this study, percent density was classified into
four categories: 0-10%, 11-25%, 26-50%, > 50%.
Statistical methods
Data were summarized using frequencies and percents
for categorical variables, and medians and ranges for
continuous variables. Associations of MBD with demo-
graphic and clinical variables were first assessed using
chi-square tests of significance. All variables that were
univariately statistically significant were then included in
a multivariate logistic regression model to assess the in-
dependent effects of these characteristics.
To reduce the possibility of including women with
subclinical BC at benign biopsy, women did not contrib-
ute person years of observation until six months post-
biopsy. Duration of follow-up was calculated as the
number of days from that date to the date of BC diagno-
sis, death, or last contact. In addition, women with
prophylactic mastectomies or a diagnosis of lobular car-
cinoma in situ (LCIS) were censored at the date of such
occurrence. We estimated relative risks (RR) using stan-
dardized incidence ratios (SIRs) and corresponding 95%
confidence intervals (CI), dividing the observed numbers
of incident BCs by the population-based expected
counts. We calculated expected counts by apportioning
each woman’s follow-up into 5-year age groups and mul-
tiple calendar periods, thereby accounting for differences
associated with these variables. We used the Iowa
Surveillance, Epidemiology, and End Results (SEER)
registry as the reference population because of its demo-
graphic similarities to the Mayo population (80% of co-
hort members reside in the Upper Midwest). SIRs were
calculated both overall and within subgroups defined by
histologic, clinical and demographic characteristics. We
assessed potential heterogeneity in SIRs across sub-
groups using Poisson regression analysis, with the log
transformed expected event rate for each individual
modeled as the offset term.
Cox proportional hazards regression analysis was used
to estimate intra-cohort MBD hazard ratios after
adjustment for demographic and clinical variables.
Statistical tests were two-sided, and analyses were con-
ducted with use of SAS statistical software version 9.4
(SAS Institute Inc., Cary NC). A p-value < 0.05 was
treated as significant.
Results
Of the 7999 women in the BBD cohort diagnosed be-
tween 1985 and 2001, 6271 (78.4%) had MBD data
within one year prior to biopsy (3532 with NP, 2269 with
PDWA and 470 with AH). A summary of the number of
women by levels of histologic impression, MBD, BMI
and breast cancer status can be found in Additional file
1. Older women were more likely to have MBD values
than younger women. MBD data availability did not dif-
fer significantly across year of biopsy, number of atypical
foci, type of atypia (ADH vs. ALH), extent of lobular in-
volution or body mass index, (p-value > 0.05 for each,
data not shown).
We observed an association between histologic cat-
egory of BBD and MBD, in that women with NP were
more likely to fall into the low MBD category (699/3532,
19.8%) than those with PDWA (364/2269, 16.0%) or AH
Fig. 1 Pattern of mammographic density and corresponding sample sizes. Categories of mammographic density based on parenchymal pattern (PP)
and BI-RADS density. Panels from left to right display representative examples of low MBD (PP category N1 [N = 60] and BI-RADS category “fatty” [N= 9];
moderate MBD (PP categories P1 [N = 32] or P2 [N = 59], and BI-RADS categories “scattered” [N= 55]or “heterogeneously dense” [N = 85]); and high MBD
(PP category DY [N= 131] and BI-RADS category “extremely dense” [N = 39])
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(69/470, 14.7%, chi-square p-value < 0.001). After ac-
counting for age at biopsy and BMI, results were even
more striking: women with AH were more than twice as
likely to be in the high MBD category vs. the low cat-
egory than those with NP (logistic regression odds ratio
2.10, 95% CI 1.51-2.93).
Over a median follow-up of 14.3 years for the 6271
women, 528 BCs were observed (224 in women with NP,
222 in women with PDWA and 82 in women with AH).
We observed a strong positive dose–response association
between MBD and BC risk in women with NP (test for het-
erogeneity in SIRs p < 0.001), and a modest but non-
significant association in women with PDWA (p = 0.27,
Table 1). In contrast, risk of breast cancer did not appre-
ciably differ across density categories for women with AH
(SIR for low density 3.40, for moderate density 3.48, and for
high density 3.25, test for heterogeneity p-value = 0.96,
Table 2). BC cumulative incidence curves also overlapped
considerably across the three levels of extent of MBD for
these women (Fig. 2). Tests for interaction between histo-
logic impression (modeled as a categorical variable) and
MBD (modeled as an ordinal variable) revealed that histo-
logic impression significantly modified the association be-
tween MBD and breast cancer risk (p = 0.03). Because the
null finding in AH differed from what we had seen in the
other two histologies, we examined the subset of women
with AH more closely. Of the 470 eligible women with AH,
69 (15%) had low, 231 (49%) had moderate, and 170 (36%)
had high extent of MBD, respectively. Associations of MBD
with demographic and clinical characteristics in women
with AH are provided in Table 2. Univariate results showed
several associations with MBD. After multivariate adjust-
ment, age at biopsy (p = 0.001), type of MBD measurement
(p < 0.001), degree of lobular involution (p = 0.03), and BMI
(p < 0.001) remained statistically significant. Compared to
women with high MBD values, those with low values
tended to be older, to have a higher BMI, and to have more
extensive LI. In addition, women with high or low MBD
were more likely to have had a PP density measurement.
Comparisons of clinical and demographic characteristics
by type of density measure (BIRADS versus PP) in women
with AH revealed very few differences (Additional file 2).
Women with BI-RADS density values were slightly more
likely to have been diagnosed with ADH (either alone or
in combination with ALH) than those with PP values
(60.6% vs. 48.6%). No other attributes differed across
MBD measurement type, supporting our decision to com-
bine the two MBD measurement types.
We also examined associations between MBD and
breast cancer risk within subsets of women with AH. We
found no evidence of heterogeneity in risk by MBD when
examining subsets defined by type of MBD measure (PP
vs. BI-RADS), age at benign biopsy, number of atypical
foci, type of AH, or BMI, although sample sizes in some of
these subsets were small (Table 3).
Due to concerns that both the PP and BI-RADS MBD
measures are subjective, we conducted a series of sensitiv-
ity analyses in a group of 212 women (with 32 resulting
BC events) for whom mammographic percent density
(PD) was available. Results are provided in Table 4. Risk of
breast cancer did not appreciably differ across the lower
three PD categories (SIR 2.54 for 0-10%, 3.75 for 11-25%,
and 2.94 for 26-50%). We observed an SIR of 4.98 (95% CI
0.60-17.92) for women with >50% PD, but this category
included only 8 subjects and 2 observed breast cancer
events, resulting in a very imprecise point estimate. As
with the primary analyses, the test for heterogeneity in the
SIRs was non-significant (p = 0.76)
Primary analyses combined the middle two categories
of the PP and BI-RADs MBD measures, but secondarily
we examined associations with BC risk within each of
the four categories. Results were similar for PP P1 (SIR
3.62, CI 1.46-7.45) and P2 (SIR 2.89, CI 1.39-5.32), and
for scattered (SIR 3.49, CI 1.60-6.64) and heterogeneously
dense BI-RADS density categories (SIR 3.95, CI 2.21-6.51,
Additional file 3). Sensitivity analyses retaining the original
four-level density values and testing for trend across these
values also yielded null results (p = 0.83).
Due to concerns that associations of MBD with BC risk
may differ depending on time since initial biopsy, we ran
sensitivity analyses subsetting to the first 10 years of post-
biopsy follow-up. Findings were similar to our overall
Table 1 Associations of extent of mammographic breast density with breast cancer risk by levels of benign histologic impression
Low Density Medium Density High Density p-valuea
Characteristic N Obs Exp SIR (95% CI) N Obs Exp SIR (95% CI) N Obs Exp SIR (95% CI)
Histologic Impression
NP 699 30 40.07 0.75 (0.50, 1.07) 1586 99 80.27 1.23 (1.00, 1.50) 1247 95 56.69 1.68 (1.36, 2.05) <0.001
PDWA 364 31 22.15 1.40 (0.95, 1.99) 1104 113 58.76 1.92 (1.58, 2.31) 801 78 43.50 1.79 (1.42, 2.24) 0.27
AH 69 12 3.53 3.40 (1.76, 5.93) 231 41 11.77 3.48 (2.50, 4.73) 170 29 8.92 3.25 (2.18, 4.67) 0.96
Standardized incidence ratios and corresponding 95% confidence intervals, comparing the observed number of breast cancer events to those expected based on
incidence rates from Iowa SEER data. Analyses account for the effects of age and calendar period
NP non-proliferative disease, PDWA proliferative disease without atypia, AH atypical hyperplasia, N number of individuals, Obs observed number of breast cancer
events, Exp expected number of breast cancer events, SIR standardized incidence ratio, CI confidence interval
aP-value, test of heterogeneity in SIRs across columns
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results: SIR 4.11 (95% CI 1.97-7.56) for low MBD, 3.27
(2.14-4.80) for moderate MBD, and 3.63 (2.18-5.67) for
high MBD respectively (test for heterogeneity p = 0.82).
Also, because analysis of BC risk using SIRs does not
allow for formal adjustment of certain potential confound-
ing variables, we re-examined MBD risk associations using
intra-cohort Cox proportional hazards regression analyses
(Additional file 4). We again found no evidence of associ-
ation after adjustment for age at biopsy, BMI, type of
MBD measure (when applicable) and extent of involu-
tion (p = 0.69 using the PP/BI-RADS density measure
and p = 0.47 using the PD measure). Further analyses
modeling PD as a one degree-of-freedom linear term, first
using the original PD values (p = 0.57) and then using
square-root-transformed values (p = 0.58) yielded similar
results.
Finally, we limited events to only the 65 invasive breast
cancers, censoring women with DCIS at date of diagno-
sis. Although SIRs did order in the hypothesized
Table 2 Associations of mammographic breast density with demographic and clinical variables
Characteristic Low (N = 69, 15%) Moderate (N = 231, 49%) High (N = 170, 36%) Total (N = 470) p-valuea Multivariate p-valueb
Age at Benign Biopsy <0.001 0.001
< 45 7 (10.1%) 15 (6.5%) 32 (18.8%) 54 (11.5%)
45-55 9 (13.0%) 76 (32.9%) 67 (39.4%) 152 (32.3%)
55+ 53 (76.8%) 140 (60.6%) 71 (41.8%) 264 (56.2%)
Type of Density Measure <0.001 <0.001
BI-RADS 9 (13.0%) 140 (60.6%) 39 (22.9%) 188 (40.0%)
PPAT 60 (87.0%) 91 (39.4%) 131 (77.1%) 282 (60.0%)
Number of Atypical Foci 0.31
1 47 (68.1%) 126 (54.5%) 96 (56.5%) 269 (57.2%)
2 15 (21.7%) 61 (26.4%) 42 (24.7%) 118 (25.1%)
3+ 7 (10.1%) 44 (19.0%) 32 (18.8%) 83 (17.7%)
Type of Atypia 0.004 0.11
ADH 41 (59.4%) 116 (50.2%) 65 (38.2%) 222 (47.2%)
ALH 27 (39.1%) 96 (41.6%) 96 (56.5%) 219 (46.6%)
ADH and ALH 1 (1.4%) 19 (8.2%) 9 (5.3%) 29 (6.2%)
Involution <0.001 0.03
Missing 2 11 7 20
None 1 (1.5%) 19 (8.6%) 26 (16.0%) 46 (10.2%)
Partial 41 (61.2%) 124 (56.4%) 112 (68.7%) 277 (61.6%)
Complete 25 (37.3%) 77 (35.0%) 25 (15.3%) 127 (28.2%)
BMI <0.001 <0.001
Missing 1 2 2 5
< 25 25 (36.8%) 78 (34.1%) 101 (60.1%) 204 (43.9%)
25-29 19 (27.9%) 70 (30.6%) 35 (20.8%) 124 (26.7%)
30+ 24 (35.3%) 81 (35.4%) 32 (19.0%) 137 (29.5%)
Values presented as number (percent)
a Chi-square tests
b Multicategorical nominal logistic regression analysis modeling extent of density as the outcome variable. Model includes all variables found to be univariately
significant (p < 0.05)
Fig. 2 Cumulative breast cancer incidence by extent of mammographic
breast density in women with atypical hyperplasia. Curves account for
death as a competing event
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direction (SIRs = 2.62 for low, 3.09 for moderate, and
3.45 for high MBD respectively), relative effect sizes
were small and did not approach statistical significance
(test for heterogeneity p = 0.78). We found no associ-
ation of MBD with invasive breast cancer using Cox re-
gression analyses (HRs = 1.08 and 1.08 for moderate and
high MBD relative to low MBD, p = 0.98).
Discussion
We found the MBD and breast cancer association dif-
fered by histologic impression. In particular, there was a
strong association among women with NP and a sug-
gestive association among PDWA. However, in our co-
hort of 470 women diagnosed with AH, we found no
convincing evidence of an association between
Table 3 Associations of extent of mammographic breast density with breast cancer risk in women with atypical hyperplasia
Low Density Medium Density High Density p-valuea
Characteristic N Obs Exp SIR (95% CI) N Obs Exp SIR (95% CI) N Obs Exp SIR (95% CI)
Overall 69 12 3.53 3.40 (1.76, 5.93) 231 41 11.77 3.48 (2.50, 4.73) 170 29 8.92 3.25 (2.18, 4.67) 0.96
Type of Density Measure
PPAT 60 11 3.16 3.48 (1.74, 6.23) 91 17 5.39 3.15 (1.84, 5.05) 131 24 7.33 3.28 (2.10, 4.87) 0.97
BIRADS 9 1 0.37 2.73 (0.07, 15.13) 140 24 6.37 3.77 (2.41, 5.60) 39 5 1.59 3.14 (1.02, 7.31) 0.89
Age at Biopsy
< 45 7 2 0.30 6.61 (0.80, 23.79) 15 2 0.32 6.17 (0.75, 22.21) 32 4 1.20 3.33 (0.91, 8.53) 0.66
45-55 9 0 0.39 NA 76 15 3.64 4.12 (2.31, 6.80) 67 14 3.65 3.84 (2.10, 6.44) 0.21
55+ 53 10 2.84 3.53 (1.69, 6.49) 140 24 7.80 3.08 (1.97, 4.58) 71 11 4.07 2.70 (1.35, 4.84) 0.83
Number of Atypical Foci
1 47 6 2.73 2.20 (0.81, 4.79) 126 19 6.80 2.79 (1.68, 4.36) 96 16 4.76 3.36 (1.92, 5.46) 0.65
2 15 4 0.52 7.73 (2.11, 19.81) 61 14 2.81 4.98 (2.72, 8.36) 42 6 2.42 2.48 (0.91, 5.40) 0.16
3+ 7 2 0.29 6.98 (0.84, 25.13) 44 8 2.15 3.72 (1.61, 7.32) 32 7 1.74 4.03 (1.62, 8.29) 0.76
Type of Atypia
ADH 41 7 2.18 3.21 (1.29, 6.61) 116 17 5.74 2.96 (1.73, 4.75) 65 15 3.48 4.31 (2.41, 7.11) 0.57
ALH 27 5 1.28 3.92 (1.27, 9.12) 96 20 5.14 3.89 (2.38, 6.01) 96 13 4.92 2.64 (1.40, 4.52) 0.51
ADH and ALH 1 0 0.08 NA 19 4 0.89 4.48 (1.22, 11.48) 9 1 0.51 1.94 (0.05, 10.79) 0.56
BMI at Biopsy
< 25 25 2 1.45 1.38 (0.17, 4.97) 78 18 3.96 4.55 (2.69, 7.19) 101 17 5.17 3.29 (1.91, 5.27) 0.16
25-29 19 5 1.01 4.96 (1.61, 11.55) 70 10 3.37 2.97 (1.42, 5.46) 35 4 1.95 2.05 (0.56, 5.25) 0.42
30+ 24 5 1.07 4.66 (1.51, 10.86) 81 13 4.39 2.96 (1.57, 5.07) 32 7 1.76 3.97 (1.60, 8.17) 0.65
Standardized incidence ratios and corresponding 95% confidence intervals, comparing the observed number of breast cancer events to those expected based on
incidence rates from Iowa SEER data. Analyses account for the effects of age and calendar period
N number of individuals, Obs observed number of breast cancer events, Exp expected number of breast cancer events, SIR standardized incidence ratio, CI
confidence interval
aP-value, test of heterogeneity in SIRs across columns
Table 4 Associations of percent mammographic breast density (PD) with breast cancer risk in a subgroup of women with atypical
hyperplasia
Characteristic No. Women Person Years Observed Events Expected Events SIR (95% CI) p-valuea
Overall 212 2469 32 10.15 3.15 (2.16, 4.45)
Percent Density 0.76
0-10% 59 688 8 3.15 2.54 (1.10, 5.00)
11-25% 69 777 12 3.20 3.75 (1.94, 6.55)
26-50% 76 900 10 3.41 2.94 (1.41, 5.40)
51 + % 8 104 2 0.40 4.98 (0.60, 17.92)
Standardized incidence ratios and corresponding 95% confidence intervals, comparing the observed number of breast cancer events to those expected based on
incidence rates from Iowa SEER data
Analyses account for the effects of age and calendar period
aP-value, test of heterogeneity in SIRs
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mammographic breast density and subsequent risk of
BC. Null associations persisted within most of the AH
subsets and after adjustment for relevant demographic
and clinical variables. The only subgroup suggesting a
difference in BC risk was women with percent density >
50%, but this result was based on just eight subjects and
two breast cancer events. These results are in contrast
to women with non-proliferative disease, for whom high
MBD was strongly associated with increased BC risk.
Our findings are consistent with those from a nested
case–control study using women with biopsies enrolled
in the Breast Cancer Detection Demonstration Project
[16]. In this study of 347 BC cases and 410 age- and
race-matched controls, Byrne et al. examined BC risk
within categories defined by combinations of percent
density assessed by Cumulus and histologic impression.
For women with NP, they observed a strong dose–re-
sponse association with density: ORs = 1.0 (ref ) for
women with <50% density, 2.5 for PD of 50-74%, and 5.8
for PD ≥75%. This association attenuated for women
with PDWA: ORs = 1.6 for <50%, 2.5 for 50-74%, and 3.2
for ≥75%, relative to women with NP and PD < 50%.
Notably, they observed no apparent association for
women with AH (ORs = 4.1 for <50%, 3.0 for 50-74%,
and 2.1 for ≥75%), although they only had 99 women
with AH (58 cases and 41 controls).
However, our results contrast with two other studies.
Tice et al. examined BC risk with different combinations of
BBD histologic impression and MBD, as measured using
BI-RADS criteria, in more than 42,000 women in the
Breast Cancer Surveillance Consortium (BCSC), including
2179 with AH diagnosed by community pathologists as
part of a patient’s routine medical care [17]. Compared to
women with non-proliferative disease and BI-RADS cat-
egory 2, those with AH and BI-RADS category 4 were at
the greatest increased risk of BC (N = 267, RR 5.34); those
with AH and intermediate density were at intermediate
risk [BI-RADS 2 (N = 768, RR 2.57) and BI-RADS 3
(N = 1079, RR 3.37)]; and those with AH and BI-RADS
category 1 were at lowest risk (N = 65, RR 0.68), although
confidence intervals overlapped for all AH risk estimates.
The number of women with AH in this study (N = 2179)
is considerably larger than our current study (N = 470), al-
though women in our study were followed for a longer
period of time (median 13.5 years compared to 6.1). When
we limited our study to the first ten years of follow-up, we
found similar null associations compared to our overall re-
sults, albeit with lower precision of estimates.
Reimers et al. examined BC risk associations in 815
women at high risk of breast cancer, with available histo-
logic impression and with MBD data measured used the
BI-RADS criteria [18]. Their study is composed of a sub-
set of individuals enrolled in the Women at Risk Registry
who had either a strong family history of breast cancer
or a biopsy-proven history of LCIS or AH [24]. They re-
ported that in the women with AH, those with BI-RADS
values of 3 or 4 were at increased risk of BC (RR 4.40,
95% CI 2.24-8.67) compared to women with AH and BI-
RADS of 1 or 2 (RR 1.33, 95% CI 0.54-3.26), using
women with no AH and BI-RADS of 1 or 2 as the refer-
ent group. However, confidence intervals were wide and
overlapped considerably between the two AH groups.
The number of women in this study with AH was not
reported, which makes it difficult to compare to our
current study focusing only on AH. Furthermore, the
average length of follow-up was 7.9 years and the num-
ber of BC events was also not specified.
Thus, of the four studies to date examining associations
between MBD and BC risk in women with AH, two report
suggestive but non-significant results [17, 18], while ours
and Byrne et al. report decidedly null results [16]. Of note,
all four studies observed overall associations between AH
and BC risk, and between high MBD and BC risk, consist-
ent with the established views. Results differed only when
examining MBD and BC risk within the subset of AH in-
dividuals. Several possibilities for this discrepancy exist.
First, it is possible that sample size of ours and other stud-
ies were insufficient to detect statistically significant asso-
ciations. To examine this in our study, we ran a series of
post-hoc power analyses based on characteristics of our
cohort of 470 women. Assuming a two-sided test of hy-
pothesis with a Type I error rate of 0.05, the observed pro-
portions of women with low MBD and high MBD in our
study, and the total observed numbers of BC events in our
study, we would have 52% statistical power to detect a
relative risk of 2 in high MBD women compared to low
MBD women, 80% power to detect a relative risk of 2.6,
and greater than 90% power to detect relative risks of 3 or
larger. Thus, we have a sufficient sample size to pick up
large differences in BC risk similar to those found in pre-
vious non-AH studies [13, 14], but modest sample size to
pick up small or intermediate differences.
Another possible explanation for the lack of association
is that women with AH and/or high MBD may have been
selectively prescribed chemopreventive SERMs such as
tamoxifen or raloxifene to reduce their risk of BC, which
in turn could have altered any observed associations be-
tween MBD and BC risk. Among the 470 women in our
study, at least 20 had documented evidence of being pre-
scribed tamoxifen or raloxifene subsequent to initial bi-
opsy and (for the 3 of 20 who developed BC) at least six
months prior to BC diagnosis. We ran sensitivity analyses
excluding these women and still found no evidence of an
association between MBD and BC risk (SIR = 3.51 for low
MBD, 3.47 for moderate MBC, 3.33 for high MBD, test
for heterogeneity p = 0.98). None of the three other studies
mentioned prevalence of use of chemopreventive agents
in their findings. However, given the fact that clinical
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information was collected prior to 1990 for Byrne et al.
and prior to 2006 for Reimers et al., before tamoxifen and
raloxifene were commonly used preventively, it is unlikely
that these agents affected risk associations for those
studies.
A biologically viable explanation is that high MBD
promotes the development of precancerous lesions such
as AH, which in turn are associated with increased BC
risk. Perhaps high MBD provides a permissive micro-
environment for epithelial abnormalities to progress to
pre-malignancy, but once a woman progresses to AH
the density in the microenvironment has no further pro-
moting effect. MBD is composed of both epithelial and
stromal components. It is possible that the BC risk asso-
ciated with AH reflects the risk related to the epithelial
component of MBD. It is also believed that stromal
growth factors may influence the epithelium, resulting in
abnormalities such as AH which in turn influences sub-
sequent BC risk [25]. If this was the case, one would ex-
pect to see a strong positive association between MBD
and presence of AH. This indeed has been reported by
several studies, including the current one. Boyd and col-
leagues found that women with high MBD had a 9.7-fold
increased risk of developing AH and/or DCIS compared
to those with low MBD [15]. Cuzick et al. found that
women with a personal history of AH were 20 times
more likely to have high PD (defined as ≥50%) than
those with no previous breast biopsy, and 12 times more
likely to have high PD than those with non-proliferative
disease [26]. Our finding that women with AH were
more than twice as likely to have high MBD as those
with NP corroborates these results.
Although the vast majority of our results were null, we
did observe a possible increased risk in BC for women
with AH and PD > 50% (SIR 4.98, 95% CI 0.60-17.92).
However, this result did not approach statistical signifi-
cance due to the small number of women with this
phenotype and so needs to be verified in an external
cohort.
An interesting finding from this study was that women
with PP MBD measures were more likely to fall into the
high and low MBD categories than those with BI-RADS
measures, who tended to cluster in the moderate cat-
egory. This may indicate that PP is better at stratifying
levels of MBD than BI-RADS. The PP does attempt to
assess density amount/proportion and patterns (i.e.
nodular vs. diffuse), while the BI-RADS density historic-
ally emphasized proportions. Regardless, associations of
MBD with BC risk were similar in the PP and BI-RADS
subsets of women.
Our study has several notable strengths. AH for each
study participant was confirmed by a single breast path-
ologist with broad breast research experience. This is an
important consideration given the known misclassification
issues for these lesions [27]. Detailed information on clin-
ical and demographic attributes, and post-biopsy follow-up
for cancer events, was ascertained based on questionnaires
and review of Mayo Clinic’s unified medical record and
tumor registry database. It should be noted that study par-
ticipants were primarily Caucasian, and all were seen at the
same institution in the Upper Midwest, so geographic and
racial/ethnic makeup of the cohort is somewhat homoge-
neous. The PP and BI-RADS MBD measures used in our
primary analyses are subjective but clinically relevant and
have been consistently associated with BC risk [12, 28–38]
including in our own populations [39–41]. We examined
multiple measures of breast density, including PP, BI-
RADS and PD. Moreover, Byrne et al. [16] found similar
results to ours using PD measures. Finally, some of the
subset analyses resulted in small cell sizes, making it diffi-
cult to state unequivocally that there is no association
across all subgroups.
Conclusion
In summary, we evaluated the impact of mammographic
density on breast cancer risk in women with AH, based
within a cohort of women with benign breast disease.
Women with AH were more likely to have higher mam-
mographic density than women without AH. Although
mammographic density was associated with higher risk in
women without AH, it did not stratify risk in women with
AH. Therefore, our results suggest that MBD measures
may not play as important a role when making manage-
ment decisions for women with AH than for women with
other forms of benign breast disease
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